Core Viewpoint - AnuoYuda Gene Technology (Beijing) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CCB International and Guotai Junan International as joint sponsors. The company previously submitted its listing application on March 25 [1]. Company Overview - AnuoYuda specializes in molecular diagnostics-based IVD medical devices and multi-omics life science research services, particularly focusing on NGS-based prenatal testing IVD products. Its clinical sequencing solutions include self-produced IVD testing kits, gene sequencers, and bioinformatics analysis software, along with technical support and laboratory design services [3][4]. - The company's clients primarily consist of hospitals certified for prenatal diagnosis and independent medical laboratories (ICLs), which purchase IVD products and pay fees based on the quantity and type of products purchased [3]. Market Position - AnuoYuda's NIPT testing kit, aimed at detecting the three most common chromosomal disorders (trisomy 21, 18, and 13), received a Class III medical device certificate in 2017, establishing its market position in prenatal testing. According to ZhiShi Consulting, the company ranks second in the Chinese NIPT market by sample testing volume in 2024, with market shares of 11.6%, 12.1%, and 15.5% for 2022, 2023, and 2024, respectively. By revenue, the company ranks third in the Chinese NIPT market with a market share of 14.6% [3]. Business Segments - The clinical sequencing solutions business line involves sourcing reagents and equipment components from upstream suppliers, then selling IVD testing kits, proprietary gene sequencers, and bioinformatics software directly or through distributors to hospitals and independent medical laboratories. The company focuses on two IVD testing kits approved by the National Medical Products Administration, specifically for reproductive health sequencing [4]. - In the research sequencing solutions business line, the company procures gene sequencers, testing kits, and other equipment from upstream suppliers to provide six types of research sequencing solutions for academic institutions, research organizations, and corporate clients, primarily in agriculture, forestry, animal husbandry, and fisheries [4]. Production Capacity - As of September 23, 2025, AnuoYuda operates three production facilities in China, primarily manufacturing testing kits and sequencers. The combined annual production capacity during the reporting period is 40 units of NextSeq 550AR sequencers and 48,000 testing kits [4]. Financial Performance - The company reported continuous operating revenue of approximately RMB 435.145 million, RMB 474.754 million, RMB 518.088 million, and RMB 268.667 million for the six months ending June 30 in 2022, 2023, 2024, and 2025, respectively. The annual losses were approximately RMB 66.812 million, RMB 240.242 million, RMB 125.761 million, and RMB 29.006 million for the same periods [5][6].

据港交所9月30日披露，安诺优达基因科技(北京)股份有限公司(简称：安诺优达)递表港交所主板，建银国际、 国泰君安国际为其联席保荐人。该公司曾于3月25日向港交所递交上市申请。 招股书显示，安诺优达是一家专注于以分子诊断为基础的IVD医疗器械及多组学生命科学研究服务的公司，亦 专精于基于NGS的产前检测IVD产品。公司临床测序解决方案包括自产基于基因测序的IVD检测试剂盒、基因 测序仪及生物信息学分析软件，以及配套技术支持及实验室设计服务。 公司的客户主要包括产前诊断认证的医院及独立医学实验室(ICL)。该等机构客户购买公司的IVD产品，公司根 据该等客户购买IVD产品的数目及类型收取费用。 公司的NIPT试剂盒(旨在检测三种最常见的染色体疾病(21、18及13三体综合症))于2017年获得三类医疗器械证 书，并在产前检测市场建立市场地位。根据灼识咨询的资料，按样本检测量计量，于2024年，公司在中国NIPT 市场位列第二，于2022年、2023年及2024年的市场份额持续增长，分别为11.6%、12.1%及15.5%。此外，按收 入计，公司于中国NIPT市场排名第三，市场份额为14.6%。 在临床测序解决方 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Anuo Youda Gene Technology (Beijing) Co., Ltd. to provide supplementary materials regarding the cancellation of certain subsidiaries and the progress of obtaining qualifications for various IVD products and services [1][2]. Group 1: Company Operations - Anuo Youda is required to explain the reasons and progress for the cancellation of Zhejiang Anuo Youda, Anwei Kang Technology, and Yiwu Inspection Institute, and whether this has a significant adverse impact on the company's business [2]. - The company is involved in the development and commercialization of IVD products based on molecular diagnostics, focusing on non-invasive prenatal testing (NIPT) kits, sequencing instruments, and bioinformatics analysis software [6]. - Anuo Youda's NIPT kits, which detect the three most common chromosomal diseases (trisomy 21, 18, and 13), received Class III medical device certification in 2017, establishing the company as one of the early leaders in the prenatal testing market in China [7]. Group 2: Market Position - According to Zhi Shi Consulting, Anuo Youda ranked third in the NIPT market in China by sample testing volume in 2023, with market shares increasing by 9.6%, 11.6%, and 12.1% in 2021, 2022, and 2023, respectively [7]. - The company's clinical sequencing solutions include self-developed IVD testing kits and related services, with clients primarily consisting of hospitals certified for prenatal diagnosis and independent medical laboratories [6]. Group 3: Regulatory Compliance - The CSRC has requested clarification on the company's compliance with foreign investment restrictions and whether its business operations align with the necessary qualifications and regulatory requirements [2][5]. - Anuo Youda must also address any administrative penalties related to violations of the Cybersecurity Law of the People's Republic of China and the progress of any required rectifications [4].

以下文章来源于东四十条资本 ，作者鲁智高 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐"，第一时间收获最新推送 不仅是天使投资人，同时也是共同创业者。 作者丨 鲁智高 来源丨 东四十条资本 夏佐全，又有大动作。 经过十余年发展，由夏佐全天使投资并参与创业的北京明星公司——安诺优达，于近日申请在港上市。 这不禁让人想到了他的成名案例——比亚迪。1995年，夏佐全出资30万元，与王传福、吕向阳共同创办了比亚迪。到了2001年，他才正式加入比亚迪 担任执行董事、副总裁。 随着比亚迪的股价持续上涨，这笔天使投资大概率已经让夏佐全获得超过10万倍的回报。堪称神迹的操作，也让他被外界盛赞为"最牛天使"。对此，夏 佐全将之归为时代给予的机会。 在比亚迪正式任职没多久，他便于2003年成立了正轩投资。不过直到2010年辞去比亚迪副总裁一职，他才开始专职从事股权投资。安诺优达，正是正 轩投资在大健康领域布局的重点项目，并由夏佐全长期担任公司董事长。 如今，安诺优达靠着卖IVD（体外诊断）产品和提供测序解决方案，在服务医院和科研机构等客户的 ...

Core Viewpoint - Anuo Youda has submitted its listing application to the Hong Kong Stock Exchange, marking its journey towards going public, backed by influential figure Xia Zuoquan, co-founder of BYD and angel investor in UBTECH [1] Company Overview - Anuo Youda, founded in 2012 by Xia Zuoquan, specializes in IVD medical devices and multi-omics life science research services, becoming a pioneer in NGS-based prenatal testing IVD products [1][3] - The company has developed a comprehensive IVD product portfolio, including approved testing kits, sequencers, and compatible bioinformatics analysis software [3] Market Position - According to data from Zhaoshang Consulting, Anuo Youda ranks third in the Chinese NIPT market by sample testing volume, with a market share of 12.1% [2][3] - The company has significantly increased its sales of IVD products to 86 certified hospitals across 26 provinces, reflecting a growing demand for its offerings [3] Financial Performance - Anuo Youda's revenue projections for 2022 to 2024 are 435 million, 475 million, and 518 million yuan, indicating an upward trend in market demand [3] - Despite rapid business growth, the company is currently operating at a loss, with projected losses of 66.81 million, 240 million, and 126 million yuan for the same period [4] Shareholder Structure - The company boasts a strong shareholder structure, including notable investors such as China Life, Northern Light Venture Capital, Guotai Junan, Ping An Group, and Sequoia Capital, providing financial support and strategic guidance [4] - Xia Zuoquan controls 54.25% of the voting rights through direct and indirect holdings, although daily management is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industry [4][5] Leadership - Xia Zuoquan is recognized for his visionary leadership and business acumen, which are key to Anuo Youda's success, alongside CEO Li Zhimin's extensive industry insights [5]

最新数据显示，夏佐全目前个人仍位列比亚迪前十大股东之列，持股比例为2.84%，持股数达8263万股，总市值超过300亿元。 | ▶十大股东 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 实际控制人:王传福(直接持股比例:17.65%) | | | | | | | | | I | 2024-12-31 2024-09-30 | 2024-06-30 | 2024-04-12 | 2024-03-31 | 2024-03-05 | 2023-12-31 | 2023-09-30 | 2023-06-3 >> | | 名次 | 股东名称 | | | 股份类型 | 持股数(股) | 占总股本持 股比例 | 增减(股) | 变动比例 | | 1 | HKSCC NOWINEES LINED | | | 流通用股 | 1,097, 459, 799 | 37.72% | 6,100 | 0.00% | | 2 | 干传福 | | | 流通A股,限售流通A股 | 513, 623, 850 | 17. 65% | ...

来源：猎云精选，文/韩文静 千亿体外诊断赛道，即将迎来一家上市公司。 3月25日，安诺优达基因科技（北京）股份有限公司（以下简称安诺优达）递表港交所，正式申报港股IPO。 安诺优达背后站着一位知名投资人夏佐全，他曾靠投资比亚迪"一战成名"—— 上个世纪90年代，夏佐全用30万入股比亚迪，随着比亚迪成为行业"巨无霸"，夏佐全的投资回报率高达上万倍。最新的数据显示，夏佐全在比亚迪的持股数量为8263.56万股，持股比例2.84% 与此同时，夏佐全还涉入VC圈，其掌舵的正轩投资先后在先进制造、人工智能、新能源、新材料、半导体等领域投资企业40余家，其中5家公司已成功上市。 现在，夏佐全要带领安诺优达去港股IPO敲钟了。隐秘投资人夏佐全，又收获一个IPO 安诺优达成立于2012年，定位于一家聚焦于以分子诊断为基础的IVD医疗器械及多组学生命科学研究服务的公司，提供自产基于基因测序的IVD检测试剂盒、基因测序仪及生物信息学分析软件、 翻开安诺优达的招股书，其股东名单中闪现着一位著名投资人——夏佐全的身影。 上市前的股东架构中，夏佐全直接持股9.95%，通过时丰华富、安诺复琢分别持股20.74%、4.75%，通过一致行动 ...